Table 2.
Breakdown of Treatment-Related Pneumonitis Incidence by Grade According to Common Terminology Criteria for Adverse Events Version 5.0
| Pneumonitis Grade Category | Total (N = 102) | Osimertinib Overlapping (n = 22) | Osimertinib Held During RT (n = 80) |
|---|---|---|---|
| None or grade 1 | 88 (86.3) | 20 (90.9) | 68 (85.0) |
| Grade 2+ | 14 (13.7) | 2 (9.1) | 12 (15.0) |
| Pneumonitis by grade | |||
| None | 86 (84.3) | 18 (81.8) | 68 (85.0) |
| Grade 1 | 2 (2.0) | 2 (9.0) | 0 (0.0) |
| Grade 2 | 9 (8.8) | 1 (4.6) | 8 (10.0) |
| Grade 3 | 3 (2.9) | 1 (4.6) | 2 (2.5) |
| Grade 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Grade 5 | 2 (2.0) | 0 (0.0) | 2 (2.5) |
| Time to grade 2+ pneumonitis, median [range] in mo | 3.2 [1.5–6.3] | 2.2 [1.6–2.7] | 3.4 [1.5–6.3] |
Note: All values are n (%) unless otherwise specified.
RT, radiotherapy.